Book a consultation →

For neurology practices

Keep site of care exactly where it belongs — your office.

Whether you're starting infusion, growing an existing program, or bringing dispensing in-house — we help you keep more of your patients, and their care, under your roof.

Are your infusion patients staying in-office today?

THE ASSESSMENT IS FREE · NO COMMITMENT
Book a consultation
→

The problem we fix

When the infusion leaves your office, so does your control.

The site of care and the site of treatment have become two different places. Your patient gets sent to a hospital chair or shipped a drug at home — and you lose the very things that make you their physician. And if starting a program feels like one more full-time job on top of the one you already have — that's exactly the part a partner carries.

Today — the site of separation

What happens when your patient infuses elsewhere

  • Brand substitutions happen without your consent — and IVIG products are not interchangeable
  • Reactions occur where you can't observe or respond
  • You may not even know whether the patient received therapy
  • Your staff burns hours on prior auths and benefits investigations while the patient waits
With OnePulse Connect — one site of care

What changes when treatment comes to your practice

  • You control which product goes in the chair — brand continuity, every infusion
  • Your nurses monitor in real time; you're down the hall if anything changes
  • The infusion and the clinical assessment happen at the same visit — strength testing, symptom review, dose decisions at the point of care
  • AI agents run intake, benefits investigation, and prior auth — not your staff

The problem we fix

You built the program. Now make
it perform.

Standing up in-office infusion was the hard part — and you've done it. But between drug margins, payer friction, and staffing, many programs earn less than they should. Often the program has simply outgrown the person running it — that's not a staffing failure, it's the moment for a partner. We fix it without disrupting your patients.

Today — where programs leak

What quietly erodes an in-office infusion program

  • Procurement on the wrong NDC puts margins underwater — reimbursement can land below your acquisition cost
  • Your staff still burns hours on benefits investigations and prior auths for every chair
  • Payers keep pushing product substitutions and site-of-care steerage against the program you built
  • The outcomes happen in your chairs, but never become reportable quality data
With OnePulse Connect — transition & optimize

You're already doing the hard part. We make it pay.

  • Multi-NDC procurement with product continuity per your preference — margins optimized on ASP, not guesswork
  • Payer intelligence, benefit verification, and prior auth run by AI agents — off your staff's desk
  • Every visit becomes documented, reportable clinical outcomes — quality data as a byproduct of care, not another chore
  • Revenue-cycle support end to end — E/M capture, claim reconciliation, and a quarterly review of what the program earns — the model our flagship neurology partner runs

See the shift

Where do your patients infuse today?

Click to compare →

Today: your 12 infusion patients are treated at hospital chairs, home infusion, and outside pharmacies — away from your team.

Why now

Your policy advantage expires in 2033.

Two federal laws — the Inflation Reduction Act and the One Big Beautiful Bill Act — are making self-administered specialty drugs costlier and harder to access, while office-based infusion stays stable and protected. That's a policy tailwind for buy-and-bill neurology over the next 5–10 years.

Office infusion stays protected

Most neurology infusion biologics are shielded from Medicare price negotiation into 2029–2033, and IVIG is permanently excluded as a plasma-derived product.

Pharmacy-benefit drugs are getting harder

Part D deductibles and coinsurance are climbing, formularies are shrinking — and more than half of high-cost self-administered prescriptions now go unfilled at the pharmacy.

Buy-and-bill stays stable

ASP-based reimbursement has been essentially untouched by the new rules — predictable, transparent office economics for the decade ahead.
Drawn from peer-reviewed policy literature.

Quality & outcomes

Care you can measure. Outcomes you
can report.

Every figure below comes from published, peer-reviewed literature — with the source shown. These are what the in-office model delivers in the real world, not our marketing targets.

96.6%
Real-world adherence across infusion DMTs
the highest of any DMT route
↗ Neurological Sciences · 2025
8%
12-month discontinuation, in-office ocrelizumab
vs 43% for injectable DMTs
↗ J Manag Care Spec Pharm · 2021
~42%
Higher cost for the same infusion in hospital outpatient
vs a physician office — no outcome difference
↗ J Manag Care Spec Pharm · 2026
>50%
High-cost self-admin scripts abandoned at the pharmacy
buy-and-bill removes that step entirely
↗ Health Affairs · 2022
Published figures — individual results vary by drug mix and payer mix. Full citations available on request.
"We measure strength at every infusion now. The data was always there — we just never captured it while the patient sat in someone else's chair."
Neurologist, partner practice · Midwest US

Site of care, compared

Four ways your patient can infuse.
Only one keeps you in charge.

Your office, with OnePulse Connect Hospital outpatient Home infusion White-bag pharmacy
Cost of care Lowest — the baseline 42–104% higher for the same drug Similar drug cost, added risk Higher patient out-of-pocket
Who chooses the product You do — brand continuity guaranteed Hospital formulary Pharmacy supplies the drug PBM / pharmacy — switches without consent
REMS compliance Full — prescriber-supervised, on-site Compliant if enrolled Prohibited for some drugs (e.g. natalizumab) Fragmented
Safety & reactions Your team manages reactions; you're down the hall Physician available — doesn't know the patient 25% higher odds of ED visit or admission No prescriber on-site
Adherence & persistence Highest of any site — assessment at every visit Similar 28% higher discontinuation after an adverse event >50% of scripts abandoned at the pharmacy
Where the revenue goes Drug margin + admin fees stay in your practice Hospital keeps both No admin fee to your practice Margin routes to pharmacy & PBM

Figures from published literature (JAMA Network Open 2021 · Health Affairs 2021–2022 · J Manag Care Spec Pharm 2026); sourced in full on request.

Make it yours

A custom solution for each practice
— every time.

We don't force a model on you — you choose the share you keep in-office, and you stay in control. Slide to your own panel for a directional picture of what changes clinically; the real model is built from your numbers, in a conversation.

Your infusion panel today

Rough numbers are fine — set the last slider to where you are today, then to where you want to be.

100 patients
18 infusions
25%
What changes clinically
450 in-office visits / year
each one a chance to examine your patient on therapy — down the hall, not across town.
Adherence across your panel78.9%
Blends 96.6% adherence in-office (published) with 73% outside — weighted by the share you keep.
Patients under your roof25 of 100
Fits in2 chairs · 3 days a week
Revenue-cycle work (BI, PA, claims)handled by us
Have a specialist model my panel →

Directional only. Chair fit assumes a typical neurology infusion mix (IVIG-weighted, ~3.5 chair-hours per infusion) and six usable chair-hours a day; the adherence figure blends 96.6% in-office (Neurological Sciences, 2025) with 73% outside your office, weighted by the share you keep in-office. Not a projection of your practice's results — your model is prepared by our clinical-economics team from your actual drug mix, payer mix, and state, before any commitment.

What we do

One partnership. Zero extra vendors
to manage.

IVIG, biologics, and dispensing — one invoice, one nursing team, no separate pharmacy relationship to manage. You lead the medicine. We run the program with you on OnePulse Connect — suite, nursing, supply chain, and billing in one connected system, shaped around how your practice already works, with every clinical decision staying yours. Never cookie-cutter.

In-Office Infusion

Stand up a new infusion program — or transition and optimize the one you have. We run it with you, end to end.
What's included
  • Suite setup, nursing protocols & adverse-event documentation
  • Multi-NDC procurement — IVIG and beyond — with product continuity per your preference
  • Buy-and-bill billing, benefit verification & claim reconciliation
  • Condition-specific assessments at every visit

Medically Integrated Dispensing

Dispense specialty medications in-house — the full medical and pharmacy benefit under one roof, as part of the same program.
What's included
  • In-office dispensing, refills & adherence managed proactively
  • Just-in-time inventory — no waste, CMS-clean
  • Runs as one program with your infusion suite

A partnership shaped to your practice

Every engagement starts from your numbers — and stays tailored to your patients, payers, and staff.
What's included
  • Practice-specific proforma before any commitment
  • Dedicated implementation & clinical team, in your workflows
  • OnePulse Connect works behind the scenes, so your staff isn't chasing paperwork

Conditions & medications

Experience in the infusion therapies
you prescribe.

Infusion and provider-administered therapies — from long-term IVIG maintenance to MS biologics and next-generation antibodies. If you're prescribing an infusible, we can help you run it in-office.

Neurology conditions

CIDP maintenance MMN maintenance Myasthenia Gravis gMG NMOSD MS bridge therapy GBS recovery Stiff-Person Syndrome Primary immunodeficiency CVID / XLA Dermatomyositis ITP

Infusion therapies we support

IVIG — Privigen® IVIG — Octagam® IVIG — Gamunex®-C IVIG — Gammagard® Ocrevus® Tysabri® Vyvgart® Vyepti® Leqembi® Soliris® Uplizna® Briumvi® Ultomiris® Rystiggo® Actemra® Benlysta® Boniva® Cimzia® Cosentyx® Crysvita® Dupixent® Evenity® Fasenra® Ilumya® Imaavy® Kisunla® Krystexxa® Leqvio® Ocrevus Zunovo® Onpattro® Orencia® IVIG — Panzyga® Prolia® Reclast® Remicade® Risankizumab-rzaa Rituximab Saphnelo® Simponi Aria® Stelara® Tepezza® Vyvgart Hytrulo® Xolair®

Showing common neurology therapies — search to see our full list of supported infusibles.

Don't see the therapy you're running? Tell us — we work across neurology infusibles and will walk you through exactly how it would run in your practice.

Ask us about it →

Representative examples, not an exhaustive formulary. Trademarks belong to their respective owners.

Better care, controlled by the people who know the patient. The economics follow from getting the care model right.

What you can expect

From first call to first infusion —
here's the path.

1

Discovery

We run a claims-based estimate of your infusion volume and model what it's worth in buy-and-bill — before you commit to anything.

No commitment · your numbers
2

Setup & credentialing

Suite design, nursing protocols, payer enrollment, and the DSCSA-compliant supply chain — we handle the infrastructure.

We do the heavy lifting
3

Go-live

First infusions with nursing support and patient navigators in place. EMR integration handled on our side.

Typically 60–90 days
4

Grow & optimize

Payer intelligence, procurement optimization, quarterly reviews — and MIPS-ready quality data as a byproduct of the clinical program.

Ongoing partnership

What you can expect

From first call to a stronger program — here's the path.

1

Discovery

We benchmark the program you run today — drug mix, payer mix, acquisition costs, staffing load — and model the lift against your actual baseline, not a hypothetical.

No commitment · your numbers
2

Transition & layer-in

Multi-NDC procurement, payer intelligence, and clinical monitoring layered onto your existing workflow — your chairs keep running the whole time.

No disruption to patients
3

Optimize & document

ASP-optimized purchasing, claim reconciliation, E/M capture — and condition-specific assessments documented at every visit.

Revenue + quality data
4

Grow & optimize

Payer intelligence, procurement reviews, quarterly economics — and further expansion, like in-office dispensing, when and if it fits your practice.

Ongoing partnership

Physician reviews

Practices are thriving with OnePulse Connect

"

The first time an insurer tried to switch a patient's IVIG brand, we could say no — because the drug was ours, in our inventory, chosen by the physician. That's the whole point.

Medical director
Neurology practice, Mountain West
"

We thought standing up infusion meant hiring a department. It didn't. The supply chain, the nursing protocols, the billing — that arrived as a package. Our staff stopped chasing prior auths within the first month.

Practice administrator
Neurology group, Midwest US
"

My MG patients spent years being dismissed before they got here. Now they're treated by the team that knows them — and I review their assessment mid-infusion, not three days later from a note I didn't write.

Neurologist, practice owner
Multi-physician group, Southwest US

Questions physicians ask

Frequently asked questions

Getting started
We don't have space or staff for an infusion suite. Can we still do this?
Yes — that's exactly where our Startup In-Office Infusion engagement begins. Most practices start with the chairs and clinical staff they already have and scale from there. We bring the suite operations, nursing protocols, DSCSA-compliant supply chain, and billing infrastructure, and we model a right-sized ramp for your volume before you commit.
How do we know if we have enough infusion volume?
You don't have to guess. We run a no-commitment, claims-based estimate of your infusion prescribing volume — IVIG and beyond — and what it translates to in a buy-and-bill model. Even a small number of CIDP or MMN patients on regular maintenance can represent meaningful, predictable in-office volume — the analysis shows whether the program pencils before any decision is made.
How long does implementation take?
Most practices are operational within 60–90 days, with a dedicated implementation team, EMR integration handled on our side via Surescripts and Redox, and a structured onboarding program covering credentialing, payer enrollment, supply chain, and nursing workflows.
Reimbursement & risk
Isn't buy-and-bill reimbursement risky for the practice?
Reimbursement risk is real when a practice takes it on alone. In our model, benefits investigation, prior authorization, payer intelligence, and claim reconciliation are handled by our team — and every partnership starts with a proforma modeled on your actual drug mix and payer mix, so you see your economics, not a hypothetical, first.
What does the partnership cost?
Structure depends on whether we're standing up a new program or optimizing an existing one — and every engagement starts with a practice-specific proforma so you see the full economics first. No membership fees, no power of attorney over your accounts, no exclusivity clauses, no compounding annual escalators.
Dispensing (MID)
What is medically integrated dispensing — and is it legal in my state?
Medically integrated dispensing (MID) — you may also hear it called in-office or physician dispensing — means your practice dispenses the specialty medications you prescribe as part of the same clinical program, instead of routing them to an outside pharmacy. In neurology this is about your infusion and specialty therapies, not oral pharmacy-benefit drugs. Rules vary by state; we map your state's exact regulatory path during discovery, before anything is proposed.
How is MID different from our specialty pharmacy relationship?
No — this isn't about replacing your specialty pharmacy for every patient. It's about bringing the patients who are already yours back into your office. Today's arrangement routes your infusion patients away from your care team; our model keeps them with the physician and nurses who know them.
Our patients already get home infusion or white-bagged product. Why change?
Because IVIG products are not interchangeable. Under white-bagging, brand substitutions can happen without your consent, and reactions occur where you can't respond. Buy-and-bill in your office guarantees brand consistency, chain of custody, and on-site observation — with the clinical assessment at the same visit as the infusion.

Book a consultation

See what your infusion volume looks like in your own chairs.

A 30-minute conversation. We'll bring a claims-based estimate of your volume; you bring the questions.

  • A directional revenue estimate from your Medicare claims — before any commitment
  • Your state's regulatory path for in-office infusion and dispensing, mapped
  • An honest read on whether the program pencils for a practice your size
FREE ASSESSMENT · WE RESPOND WITHIN ONE BUSINESS DAY
Book a consultation
→

Copyright © 2026 Elevate Health Technologies

All Rights Reserved

|

Terms of Use

|

Privacy Policy